The tumour suppressor genes Rb and p53 are mutated in several types of human cancer, and many tumour types carry mutations in both genes. To study how these genes normally function, we and others have created mouse strains with Rb and p53 mutations. Here we describe the phenotypic effects of combined germline mutations in these two tumour suppressor genes. Mice mutant for both genes have reduced viability and exhibit novel pathology including pinealoblastomas, islet cell tumours, bronchial epithelial hyperplasia and retinal dysplasia. These data indicate that mutations in Rb and p53 can cooperate in the transformation of certain cell types in the mouse.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cell & Bioscience Open Access 22 May 2021
Signal Transduction and Targeted Therapy Open Access 02 July 2020
Nature Communications Open Access 14 April 2020
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Knudson, A.G. Antioncogenes and human cancer. Proc. natn. Acad. Sci. U.S.A. 90, 10914–10921 (1993).
Friend, S.J. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–646 (1986).
Fung, Y.K. et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science 236, 1657–1661 (1987).
Lee, W.J. et al. Human retinoblastoma susceptibility gene: cloning, identification and sequence. Science 235, 1394–1399 (1987).
Weinberg, R.A. The retinoblastoma gene and gene product. Cancer Surv. 12, 43–57 (1992).
Harris, C.C. & Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. New Engl. J. Med. 329, 1318–1327 (1993).
Malkin, D. et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
Malkin, D. p53 and the Li-Fraumeni syndrome. Cancer Genet. Cytogenet. 66, 83–92 (1993).
Van Dyke, T.A. Analysis of viral-host protein interactions and tumorigenesis in transgenic mice. Sem. cancer Biol. 5, 47–60 (1994).
Shew, H.-Y., Ling, N., Yang, X., Fodstad, O. & Lee, W.-H. Antibodies detecting abnormalities of the retinoblastoma susceptibility gene product (pp110Rb) in osteosarcomas and synovial sarcomas. Oncogene Res. 1, 205–214 (1989).
Diller, L. et al. p53 functions as a cell cycle control protein In osteosarcomas. Molec. cell. Biol. 10, 5772–5781 (1990).
Stratton, M.R. et al. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5, 1297–1301 (1990).
Rygaard, K., Sorenson, G.D., Pettengill, O.S., Cate, C.C. & Spang, T.M. Abnormalities in structure and expression of the retinoblastoma gene in small cell lung cancer cell lines and xenografts in nude mice. Cancer Res. 50, 5312–5317 (1990).
Hensel, C.H. et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50, 3067–3072 (1990).
Hensel, C.H., Xiang, R.H., Sakaguchi, A.Y. & Naylor, S.L. Use of the single strand conformation polymorphism technique and PCR to detect p53 gene mutations in small cell lung cancer. Oncogene 6, 1067–1071 (1991).
Prosser, J., Thompson, A.M., Cranston, G. & Evans, H.J. Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene 5, 1573–1579 (1990).
Varley, J.M. et al. Loss of chromosome 17p13 sequences and mutation of p53 In human breast carcinomas. Oncogene 6, 413–421 (1991).
Davidoff, A.M., Humphrey, P.A., Iglehart, J.K. & Marks, J.R. Genetic basis for p53 overexpression in human breast cancer. Proc. natn. Acac. Sci. U.S.A. 88, 5006–5010 (1991).
T'Ang, A., Varley, J.M., Chakraborty, S., Murphree, A.L. & Fung, Y.-K.T. Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 241, 1797–1800 (1988).
Varley, J.M. et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 4, 725–729 (1989).
Crook, T., Fisher, C. & Vousden, K.H. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6, 873–875 (1991).
Scheffner, M., Munger, K., Byrne, J.C. & Howley, P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. natn. Acad. Sci. U.S.A. 88, 5523–5527 (1991).
Ruggeri, B. et al. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7, 1503–1511 (1992).
Hollingsworth, J., R.E., Chen, P.-L. & Lee, W.-H. Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr. Op. cell Biol. 5, 194–200 (1993).
Michalovitz, D., Halevy, O. & Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671–680 (1990).
Martinez, J., Georgoff, I., Martinez, J. & Levine, A.J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5, 151–159 (1991).
Mercer, W.E. et al. Negative growth regulation in a glioblastoma tuumor cell line that conditionally expressed human wild-type p53. Proc. natn. Acad. Sci. U.S.A. 87, 6166–6170 (1990).
Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K.V. & Vogelstein, B. Supression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912–915 (1990).
Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304–6311 (1991).
Kastan, M. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587–597 (1992).
Shaw, P. et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. natn. Acad. Sci. U.S.A. 89, 4495–4499 (1992).
Yonish-Rouach, E. et al. Wild-type p53 induces apoptosis of myeioid leukaemic cells that is inhibited by interteukln-6. Nature 352, 345–347 (1991).
Lowe, S.W., Schmitt, E.S., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847–849 (1993).
Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytoxioity of anticancer agents. Cell 74, 957–967 (1993).
Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852 (1993).
Lee, E.Y.-H.P. et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288–295 (1992).
Jacks, T. et al. Effects of an Rb mutation in the mouse. Nature 359, 295–300 (1992).
Clarke, A.R. et al. Requirement for a functional Rb-1 gene in murine development. Nature 359, 328–330 (1992).
Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible; to spontaneous tumours. Nature 356, 215–221 (1992).
Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994).
Harvey, M. et al. Spontaneous and carcinogen-induced tumours in p53-deficient mice. Nature Genet. 5, 225–229 (1993).
Aguayo, S.M. et al. Brief report: idiopathlc diffuse hyperplasia of pulmonary endocrine cells and airways disease. New Engl. J. Med. 327, 1285–1288 (1992).
Lane, D.P. p53, guardian of the genome. Nature 358, 15–16 (1992).
Livingstone, L.R. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923–935 (1992).
Yin, Y., Tainksy, M.A., Bischoff, F.Z., Strong, L.C. & Wahl, G.M. Wild-type p53 restores cells cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937–948 (1992).
Lowe, S.W., Jacks, T., Housman, D.E. & Ruley, H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. natn. Acad. Sci. U.S.A. 91, 2026–2030 (1994).
Debbas, M. & White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546–554 (1993).
Windle, J.J. et al. Retinoblastoma in transgenic mice. Nature 343, 665–668 (1990).
Al-Ubaidi, M.R. et al. Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter. J. Cell Biol. 119, 1681–1687 (1992).
Dyson, N., Buchkovich, K., Whyte, P. & Harlow, E. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 58, 249–255 (1989).
Ewen, M.E. et al. An N-terminal transformation-governing sequence of SV40 large T antigen contributes to the binding of both p110Rb and a second cellular protein, p120. Cell 58, 257–267 (1989).
Wurtman, R.J. & Moskowitz, M.A. The pineal organ. New Engl. J. Med. 296, 1329–1333; 1383–1386 (1977).
Jakobiec, F.A., Tso, M.O.M., Zimmerman, L.E. & Danis, P. Retinoblastoma and intracranial malignancy. Cancer 39, 2048–2058 (1977).
Stannard, C., Knight, B.K. & Sealy, R. Pineal malignant neoplasm in association with hereditary retinoblastoma. Br. J. Ophthalmol. 69, 749–753 (1985).
Pesin, S.R. & Shields, J.A. Seven cases of trilateral retinoblastoma. Am. J. Ophthalmol. 107, 121–126 (1989).
Vogelstein, B. & Kinzler, K.W. The multistep nature of cancer. Trends Genet. 9, 138–141 (1993).
Hanahan, D. Transgenic mice as probes into complex systems. Science 246, 1265–1275 (1989).
About this article
Cite this article
Williams, B., Remington, L., Albert, D. et al. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7, 480–484 (1994). https://doi.org/10.1038/ng0894-480
This article is cited by
Cell & Bioscience (2021)
Signal Transduction and Targeted Therapy (2020)
Nature Communications (2020)
BMC Medical Genetics (2017)